Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.63B P/E - EPS this Y -38.90% Ern Qtrly Grth -
Income -510.45M Forward P/E -17.50 EPS next Y 33.60% 50D Avg Chg -17.00%
Sales 14.64M PEG - EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 24.17 EPS next 5Y - 52W High Chg -38.00%
Recommedations 2.00 Quick Ratio 8.51 Shares Outstanding 21.71M 52W Low Chg 247.00%
Insider Own 14.87% ROA -47.27% Shares Float 10.64M Beta -0.44
Inst Own 105.89% ROE -106.27% Shares Shorted/Prior 3.73M/3.75M Price 198.47
Gross Margin 95.66% Profit Margin - Avg. Volume 335,348 Target Price 362.53
Oper. Margin -1,110.38% Earnings Date Nov 4 Volume 225,084 Change -1.90%
About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc. News
11/22/24 Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
11/21/24 Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?
11/18/24 The first MASH drug could open the door for others — including GLP-1s
11/14/24 John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC
11/11/24 Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
11/10/24 1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
11/08/24 5 Small Drug Stocks to Buy as Trump Gets Re-Elected
11/07/24 3 High Growth Tech Stocks Leading The US Market
11/06/24 Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
11/04/24 Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations
11/02/24 Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
11/02/24 Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts
11/01/24 Madrigal Pharmaceuticals stock jumps on MASH drug hopes
11/01/24 Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
11/01/24 Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
11/01/24 Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...
10/31/24 Madrigal: Q3 Earnings Snapshot
10/31/24 Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
10/30/24 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
10/22/24 Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug
MDGL Chatroom

User Image TalkMarkets Posted - 5 hours ago

MDGL: A Promising Play In The Weight Loss Drug Space $NVO $MDGL https://talkmarkets.com/content/stocks--equities/mdgl-a-promising-play-in-the-weight-loss-drug-space?post=470224

User Image Ansselin Posted - 7 hours ago

$MDGL :;New alerts have been posted in the last hours.. allmost-wining-today.trade-smartly.xyz

User Image Richard_Roma Posted - 8 hours ago

@RJLeonii $ionq $mdgl and more risky $RGTI

User Image Jmac98 Posted - 12 hours ago

$MDGL $70 away from buying a chalet in Tahoe.… Lets fucking go. Cheers lads

User Image UVXYtrading Posted - 12 hours ago

$MDGL we fuking know $ALT is great, data is not treated the same, and $MDGL has the only approved treatment. First to market always has 68% or more of the future market. Will buy it later. Stay off the damn board, we are waiting for our buyout offer!

User Image GreenEnergy2022 Posted - 12 hours ago

$ALT Resmetirom, 46% vs our Pemv 75%. Resmetirom, Madrigal got 6B mcap. Our MASH (phs2) with FDA approved Fast Track. Data is incredible: "pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment." $MDGL $ETNB $AKRO

User Image UVXYtrading Posted - 13 hours ago

@7Billiards I will buy $ALT after $MDGL sells.

User Image Biowizard7 Posted - 13 hours ago

$MDGL What is everyone’s buyout price? Mine: $963 ($21Bn). 4.2X peak sales multiple assuming $5Bn in annual peak sales

User Image Whiskeyunderthebed Posted - 14 hours ago

$MDGL here comes the next leg up

User Image 7Billiards Posted - 14 hours ago

$ALT $MDGL $NVO $VKTX let’s all win

User Image balzofsteel Posted - 15 hours ago

$MDGL $750 $1200

User Image Idvst8 Posted - 15 hours ago

$MDGL soon. very soon

User Image Skipper6 Posted - 15 hours ago

$IOVA ...Would NOT want to be out of these 3 tickers over a weekend: $VKTX...$IOVA...$IBRX...!! Congrats to anyone still holding $MDGL!! BOL to us! Skipper

User Image SM07 Posted - 16 hours ago

Fingers crossed $MDGL is taken over before $VKTX is…!🤞

User Image Jgarcapital Posted - 16 hours ago

$MDGL moving like a BO coming

User Image UVXYtrading Posted - 17 hours ago

$MDGL here we go boys and girls!🔥🚀🧨

User Image Kelsey_King Posted - 17 hours ago

🚨 MYNZ Petra Brand Ambassador says to keep an eye on "BIG NEWS from the NFL." This is going to run parabolic soon, right after the healthcare giant Thermo Fisher ($210B mkt cap) partnered with Mainz to develop and launch together ColoAlert in US 🚀 Buy the dip now, the train is leaving very soon. $LEGN $RGEN $MDGL

User Image UVXYtrading Posted - 18 hours ago

$MDGL giddy up! Fuk $ALT until we get sold.

User Image 7Billiards Posted - 18 hours ago

last night I wrote that $ALT has better liver data than $mdgl and $vktx and better lean mass preservation than $nvo’s semaglutide with less adverse events Just wanted to hop on quick and point out that this is still true this morning.

User Image BullsOnParade79 Posted - 19 hours ago

@All_just_a_game $GALT this is our ST boards troll fondeling $MDGL balls like P Diddy

User Image 7Billiards Posted - 1 day ago

$ALT still 1/10th the market cap of $VKTX and 1/12th the market cap of $MDGL… with better liver data than MDGL and VKTX, AND better muscle preservation (almost 2x) than $NVO’s semaglutide with LESS adverse events Talk about deep value

User Image 7Billiards Posted - 1 day ago

$ALT has better clinical fibrosis results than $VKTX and $MDGL and less adverse events than $NVO’s semagultide

User Image Dark_Horse_Investments Posted - 1 day ago

$SGMT @idousky If your holdings in SGMT is a significant bulk of your portfolio and you’re experiencing a major loss (eg purchased in January), maybe a sell is for you. I’m conducting due diligence and currently own a small amount but plan to buy more. my portfolio is small relative to others but for context I am targeting to add on the drawdown about $20-$30k worth of shares. The main challenge isn't product approval but raising $200-$300 million for phase 3 trials. The compound is unique, which aligns with our strategy. The market segment has strong competition (e.g., $AKRO, $MDGL), but our unique inhibitor has potential. I don’t see $VKTX-2809 as a relevant competitor.

User Image All_just_a_game Posted - 1 day ago

$MDGL

User Image UVXYtrading Posted - 1 day ago

$MDGL LFG!

User Image Idvst8 Posted - 1 day ago

$TGTX - WOWZERS !!!!!!!! These are getting Sold. First to go is my guess $MDGL $TGTX

User Image Alligator Posted - 1 day ago

$MDGL https://www.investing.com/news/analyst-ratings/madrigal-shares-rise-as-oppenheimer-lifts-target-to-400-93CH-3733100

User Image UVXYtrading Posted - 1 day ago

$MDGL giddy up!

User Image UVXYtrading Posted - 1 day ago

$MDGL giddy up!

User Image IN0V8 Posted - 1 day ago

$MDGL Oppenheimer raises PT to $400 from $350

Analyst Ratings
Citigroup Buy Aug 8, 24
Evercore ISI Group Outperform Aug 8, 24
Cantor Fitzgerald Neutral Jul 23, 24
JMP Securities Market Outperform Jul 16, 24
Cantor Fitzgerald Neutral Jun 28, 24
Wolfe Research Outperform Jun 11, 24
B. Riley Securities Neutral May 10, 24
HC Wainwright & Co. Buy May 8, 24
Citigroup Buy May 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BAKER BROS. ADVISORS LP Director Director Dec 13 Buy 223.28 101,792 22,728,118 1,793,403 12/14/23
BAKER BROS. ADVISORS LP Director Director Dec 12 Buy 213.61 34,578 7,386,207 1,699,129 12/14/23
Lynch Brian Joseph SVP and General Coun.. SVP and General Counsel Dec 04 Sell 221.48 2,800 620,144 15,001 12/06/23
Lynch Brian Joseph SVP and General Coun.. SVP and General Counsel Dec 04 Option 82.64 2,800 231,392 16,001 12/06/23
BAKER BROS. ADVISORS LP Director Director Nov 21 Buy 187.22 64,350 12,047,607 1,667,104 11/21/23
BAKER BROS. ADVISORS LP Director Director Nov 17 Buy 178.22 67,079 11,954,819 1,607,668 11/21/23
BAKER BROS. ADVISORS LP Director Director Nov 14 Buy 159.2 49,387 7,862,410 1,545,775 11/15/23
BAKER BROS. ADVISORS LP Director Director Nov 13 Buy 146.33 107,499 15,730,329 1,500,227 11/15/23
Levy Richard S Director Director Jan 17 Sell 291.63 22,489 6,558,467 9,100 01/19/23
Levy Richard S Director Director Jan 17 Option 102.77 22,489 2,311,195 31,589 01/19/23
Lynch Brian Joseph SVP and General Coun.. SVP and General Counsel Dec 23 Sell 275.29 7,000 1,927,030 12/28/22
Lynch Brian Joseph SVP and General Coun.. SVP and General Counsel Dec 23 Option 91.79 7,000 642,530 7,000 12/28/22
Sukhija Remy Chief Commercial Off.. Chief Commercial Officer Dec 23 Sell 275.27 30,000 8,258,100 12/28/22
Sukhija Remy Chief Commercial Off.. Chief Commercial Officer Dec 23 Option 60.26 30,000 1,807,800 30,000 12/28/22